Patient Case Studies and Panel Discussion: Leukemia – Rare and Emerging Subtypes
Because of the therapeutic advances and clinical research affecting the management of hematologic malignancies, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care. The activity will include facilitated discussions during which patient cases will be examined from multidisciplinary perspectives. NCCN is inviting clinicians in the general hematology/oncology community to submit cases in these topic areas. Selected case studies will be reviewed by the panel of experts and community practitioners during interactive discussions. Panelists will offer opinions and recommendations, and they will have an immediate opportunity to review and discuss the responses of the audience.
This information was originally presented at the NCCN 2019 Annual Congress: Hematologic Malignancies™ held in San Francisco, CA, on September 27-28, 2019.
Target Audience
This educational program is designed to meet the educational needs of the interprofessional oncology care team, including: physicians/oncologists, nurses, physician assistants, pharmacists, and other healthcare professionals who manage patients with cancer.
Learning Objectives
Following this program, participants should be able to:
- Identify clinical challenges in managing patients with leukemia.
- Develop an evidence-based approach for the management of these patients.
Moderated by:
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Panelists:
Jarrod Holmes, MD
Annadel Medical Group
Nitin Jain, MD
The University of Texas MD Anderson Cancer Center
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Daniel A. Pollyea, MD, MS
University of Colorado Cancer Center
William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee; Scientific Advisor
Adaptive Biotechnologies Corporation: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
BeiGene: Grant/Research Support; Other Financial Benefit
Celgene Corporation: Consulting Fee
Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Grant/Research Support
MorphoSys AG: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee
Pharmacyclics: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support
Nitin Jain, MD
AbbVie, Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Adaptive Biotechnologies: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
ADC Therapeutics: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support
Cellectis: Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Incyte Corporation: Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee; Honoraria; Scientific Advisor
Pfizer Inc.: Grant/Research Support
Pharmacyclics: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Precision Biosciences: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Servier: Grant/Research Support
Verastem, Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Jae Park, MD
Allogene Therapeutics: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Incyte Corporation: Consulting Fee
Kite Pharma: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
Daniel A. Pollyea, MD, MS
AbbVie, Inc.: Scientific Advisor
Agios, Inc.: Scientific Advisor
Celgene Corporation: Scientific Advisor
Daiichi- Sankyo Co.: Scientific Advisor
Forty Seven, Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Scientific Advisor
Pfizer Inc.: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor
William G. Wierda, MD, PhD
AbbVie, Inc. Grant/Research Support
Acerta Pharma: Grant/Research Support
Cyclacel Pharmaceuticals, Inc.: Grant/Research Support
Genentech, Inc. Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
GlaxoSmithKline/Novartis Pharmaceuticals Corporation: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Juno Therapeutics, Inc.: Grant/Research Support
Kite Pharma: Grant/Research Support
Loxo Oncology, Inc.: Grant/Research Support
miRagen Therapeutics, Inc.: Grant/Research Support
Oncternal Therapeutics, Inc.: Grant/Research Support
Pharmacyclics: Grant/Research Support
Sunesis Pharmaceuticals, Inc.: Grant/Research Support
Xencor, Inc.: Grant/Research Support
The faculty listed below discloses no relevant financial relationships:
Jarrod Holmes, MD
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair; Kathy Ann Smith, CHCP
The NCCN Leadership listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Wui-Jin Koh, MD; Gary J. Weyhmuller, MBA, SPHR
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Mary Anne Bergman; Lydia Hammond, MBA; Alyse Johnson-Chilla; Ndiya Ogba, PhD; Dorothy A. Shead, MS; Hema Sundar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.04 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hours (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-19-091-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Catergory 1 CME credit for activities planned in accordance with AAPA CME criteria. This activity is designated for 1.0 AAPA Catergory 1 CME credits. Approval is valid until October 31, 2020. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.04 ANCC contact hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing